David Altshuler, Vertex CSO
October 9, 2023 09:00 AM EDT
People
R&D

Ex­clu­sive: Ver­tex CSO David Alt­shuler talks non-opi­oid pain pills, AI and the myth of break­throughs

Andrew Dunn

Senior Biopharma Correspondent

Short­ly af­ter jump­ing from acad­e­mia to in­dus­try in 2015, David Alt­shuler helped an­swer an ex­is­ten­tial ques­tion for Ver­tex Phar­ma­ceu­ti­cals. The Boston biotech was rid­ing high …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times